AI选股记录
总览这个股票来自自动 AI 选股池。以后只要 CLI 写入新的 ticker，这里会自动生成个股页面，不需要手工补页面。
基本信息
成交结构
基于近 60 日量价数据观察资金强弱。
交易信号历史
按时间回看该股票被模型捕捉到的买点信号。
| 信号日期 | 模型来源 | 评分/强度 | 信号价格 | 止损价 | 止盈价 | 当前表现 | 操作结论 |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | 动量强势 | +47.5% | $17.36 | $15.28 | $21.53 | -6.3% | 可买入 |
| 2026-08-13 | 动量强势 | +43.3% | $17.11 | $15.06 | $21.22 | -5.0% | 可买入 |
| 2026-08-12 | 动量强势 | +47.5% | $17.22 | $15.15 | $21.35 | -5.6% | 可买入 |
公司简介
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
